To determine whether the use of [18F]2-fluoro-2-deoxyglucose positron emission tomography (FDG PET) in addition to computed axial tomography (CT) is helpful in managing recurrent colorectal cancer (CRC).
Objective
To determine whether the use of [18F]2-fluoro-2-deoxyglucose positron emission tomography (FDG PET) in addition to computed axial tomography (CT) is helpful in managing recurrent colorectal cancer (CRC).
Summary Background Data
There is no consensus on a management algorithm for CRC. However, when recurrence is suspected, CT is generally used for further evaluation and staging of disease.
Methods
The authors used decision trees based on theoretical models to assess the cost-effectiveness of a CT ϩ FDG PET strategy for the diagnosis and management of recurrent CRC compared with a CT-alone strategy. These theoretical models focus on patients with hepatic recurrence who are potentially curable through surgical hepatic resection. The population entering the decision trees consisted of patients with CRC who had undergone surgical resection of their primary CRC and who were suspected of having recurrence based on elevated levels of carcinoembryonic antigen.
Results
The CT ϩ FDG PET strategy was found to be cost-effective for managing patients with elevated carcinoembryonic antigen levels who were candidates for hepatic resection. The CT ϩ FDG PET strategy was higher in mean cost by $429 per patient but resulted in an increase in the mean life expectancy of 9.527 days per patient.
Conclusions
These results show, through rigorous decision tree analysis, the potential cost-effectiveness of FDG PET in the management of recurrent CRC. The decision trees can be used to model various features of the management of recurrent CRC, including the cost-effectiveness of other newly emerging technologies.
In the United States, the number of new cases of colorectal cancer (CRC) was estimated at 129,400 in 1999. 1 CRC is the third most frequent cause of death from cancer, with approximately 56,600 of the new cases resulting in death. 1 Curative surgical resection of the primary CRC is a potential intervention for approximately 70% (Ϸ50,960) of the patients who do not initially die of this disease. How-ever, after curative surgery, approximately 40% (Ϸ20,384) of these patients who underwent resection of their primary CRC develop recurrence within 2 years. 2 According to the statistics in the peer-reviewed literature, [1] [2] [3] [4] [5] approximately 28% (Ϸ5,708) of these patients annually have an elevated level of carcinoembryonic antigen (CEA).
There is no consensus as to a procedure for monitoring these patients after resection of their primary CRC. 6, 7 Some studies have attempted to show that follow-up of postsurgical patients may be unnecessary, 8, 9 whereas others have shown that many of these patients can benefit substantially from monitoring after surgery. 10 This dilemma is largely due to inconsistent performance of many of the conventional imaging techniques, such as computed axial tomography (CT), magnetic resonance imaging, and ultrasonography, used to detect recurrent CRC.
In most patients, surgical resection is an option for recurrent CRC only when it is isolated to one anatomic site. Studies have shown that based on the results of conventional imaging, approximately 30% of postsurgical patients with recurrence have apparently limited recurrence, making them potential candidates for surgery. 11 However, of these candidates, only approximately 25% can truly benefit from surgery. 12 The liver is one of the most common sites of recurrence in these postsurgical patients. 2, 13, 14 Resection of recurrent CRC that is limited to the liver has been shown to be a beneficial surgical intervention, resulting in potential disease-free survival for 20 years or more. [15] [16] [17] [18] However, because of inaccurate presurgical evaluation, approximately 40% to 50% of patients who were thought to have resectable liver disease were found at surgery to have unresectable disease. 19 These patients undergo unnecessary surgery, with its risks of death and complications, and accrue extensive medical costs.
The Health Care Financing Administration recently set approximately $2,000 as an approximate global (technical, professional, tracer) fee for reimbursement of [18F]2fluoro-2-deoxyglucose positron emission tomography (FDG PET) for use in diagnosing recurrent CRC. Although FDG PET costs more than conventional imaging modalities, studies have shown its potential cost-effectiveness in the management of certain cancers. 2,20 -23 In an attempt to decrease the cost, new coincidence imaging technology is allowing the development of less expensive cameras that also use FDG, with a decrease in accuracy relative to PET. 24, 25 No studies have attempted to evaluate quantitatively the cost-effectiveness of FDG PET in the management of patients with recurrent CRC. In this study, we determined through quantitative modeling the potential cost-effectiveness of a CT ϩ FDG PET strategy versus a CT-alone strategy for postsurgical patients suspected to have recurrence, using theoretical decision tree models and sensitivity analysis.
METHODS
We defined recurrent CRC as CRC detected after surgical resection of the patient's primary CRC. Patients entering our tree included those with an increase in CEA levels of more than 5 ng/mL during follow-up testing after resection of their primary CRC. CEA testing is the most commonly used diagnostic test for monitoring potentially recurrent CRC. 26 Although the usefulness of CEA as a marker for recurrent CRC has been brought into question, 3, 27 many studies have shown that CEA testing should be used to monitor postsurgical patients. 4, 5, 13 Further, the guidelines of the National Comprehensive Cancer Network 28 for monitoring postsurgical patients suggest that independent of other tests, an elevated CEA level should warrant a complete workup of conventional imaging studies to evaluate the whole body for recurrent CRC.
A preliminary tree was used to create the population of patients entering our main decision tree (follow-up positive patients). Patients entering this preliminary tree were postsurgical patients being monitored with CEA testing. The prevalence of recurrent CRC for this population was determined through the literature. The CEA sensitivity and specificity values used in the tree were also found in the literature where an elevated CEA level (positive) was defined as an increase of 5 ng/mL from a patient's CEA levels immediately after primary CRC resection (Table 1) . [3] [4] [5] All patients diagnosed as CEA-positive (true-positive and falsepositive results) based on this threshold represented the follow-up positive population. The prevalence of CRC recurrence in the follow-up population was calculated as the total number of patients with true-positive results divided by the total number of the patients with true-positive and false-positive results.
The study population was divided into three categories: patients with recurrent CRC involving the liver (hepatic involvement); patients with recurrent CRC in locations throughout the whole body, other than the liver (extrahepatic only); and patients with no recurrence. This allowed simplification of the mathematical formulas in the tree and made the specific effects of FDG PET in the management model easier to distinguish. The patients in the hepatic involvement category all had CRC recurrence in the liver. This category could be divided into patients with isolated liver recurrence and patients with liver along with concurrent recurrences elsewhere in the body.
Our model focused on identifying patients with isolated liver recurrence to be considered for curative hepatic resection. 29 -31 The literature shows the benefits of surgical hepatic resection at the expense of relatively low rates of death and complications. 2, 32, 33 Some but not all of the patients with limited liver recurrence were candidates for surgery. This was not specifically modeled in our decision trees because the current literature does not provide adequate data on the sensitivity and specificity of conventional imaging for specific hepatic resectability issues. However, to maintain the integrity of each strategy's ability to identify patients with isolated liver recurrence, we created a variable in our decision trees that allowed a percentage of these patients to have isolated unresectable liver recurrence. When more information becomes available, future decision trees will model the specific determination of hepatic resectability.
Quantitative methods of decision analysis were used to determine cost-effectiveness. 34, 35 The determination of cost-effectiveness involved four major components. Two competing strategies, described below, were used to develop the decision tree models as described by Gambhir et al. 21 Mean and range for all variables used in the decision tree were determined through comprehensive literature searches using the Medline database from 1980 to 1999. Space prevents us from detailing the search results related to each variable. The incremental cost-effectiveness ratio (ICER)-(COST a -COST b )/(LE a -LE b ), where LE is life expectancy-was used to compare the CT ϩ FDG PET strategy with the CT-alone strategy, as described by Gambhir et al. 21 Finally, sensitivity analysis was used on all variables in our decision tree because of the uncertainty level of some of the literature-derived variables. 36 By evaluating the outcomes of the decision tree over a variable's range, the threshold point can be determined for variables with a significant effect on the ICER. This threshold point is the value of the variable where the ICER for the comparison of the CT ϩ FDG PET strategy versus the baseline strategy reached $50,000 per year, the maximum ICER accepted by many health care economists as indicating a cost-effective strategy. 37, 38 Development and analysis of the decision trees were accomplished using new software (MD@) developed in our laboratories 39 and the Data 3.0.18 (TreeAge Software, Inc., Williamstown, MA) software packages.
We also conducted an analysis after all variables favorable to FDG PET were penalized by 15%. This differed from the one-way sensitivity analysis performed because it entailed shifting multiple variables for a single analysis. The effect of inflating all variables favorable to the CT-alone strategy by 15% while maintaining the 15% penalty on favorable FDG PET variables was also explored. These scenarios were designed to show the robustness of the cost-effectiveness strategy to the simultaneous incorrect estimation of several variables. 
Strategies
We compared a CT-alone strategy with a CT ϩ FDG PET strategy ( Fig. 1 ). In the CT-alone strategy, patients were evaluated with CT of the thorax, abdomen, and pelvis. All positive CT findings were verified through biopsy. The medical condition of a patient found through this strategy warranted the following medical decisions. Patients diagnosed as positive for recurrence in the liver and negative elsewhere in the body were directed to surgery. Those thought to have extrahepatic recurrent disease were directed to chemotherapy regardless of the presence of disease in the liver. When a patient was found to be negative for recurrence, he or she recycled through the tree one time and underwent the same management strategy. At the end of the second set of testing, if the patient was still found to be negative for recurrence, no treatment was given. This strategy represents what is suggested for management of these patients and served as the baseline strategy for our analysis.
The CT ϩ FDG PET strategy was initially identical to the CT-alone strategy. All patients underwent CT imaging of the thorax, abdomen, and pelvis. After the CT scan, an FDG PET scan was incorporated when the CT was negative extrahepatically. Patients with positive CT findings underwent biopsy and were not evaluated with FDG PET. For patients diagnosed with both CT and FDG PET, a management decision was made without the use of biopsy when the imaging findings of the two modalities were concordant. A management decision for a patient with discordant imaging findings was made after biopsy. The different medical conditions diagnosed for these patients through this strategy warranted the same management decisions described for the CT-alone strategy.
In both strategies, biopsy was set at 100% accurate. If a patient had an extrahepatic positive biopsy, surgery was avoided. If an imaging finding demonstrated a positive lesion in the liver but the biopsy showed this lesion to be negative, surgery was also avoided. Performing a biopsy based on FDG PET information alone was assumed to be possible. In the clinical setting, it is difficult and often impossible to perform a biopsy based only on a positive PET finding. In the CT ϩ FDG PET strategy, all positive CT findings outside the liver were further evaluated with biopsy rather than FDG PET. Table 2 describes the details of the ICER calculations for the baseline analysis, the 15% FDG PET penalized analysis, and the 15% FDG PET penalized with 15% CT inflation analysis. All cost values were rounded to the nearest dollar, and all LE values were rounded to the nearest thousandth of a year. Through the baseline analysis of the decision tree, a mean cost for the CT ϩ FDG PET strategy was found to be $8,783; the CT-alone strategy resulted in a mean cost of $8,354. The addition of FDG PET resulted in an increase in cost of $429 per patient. This increase in cost was accompanied by a gain in LE of 9.527 days) compared with the CT-alone strategy. ICER was calculated at $16,437 per life-year saved. In our baseline analysis, 2.77% of all patients entering our tree would be correctly directed away from surgery by the additional FDG PET scan. Of the approximately 6,000 postsurgical patients per year with an elevated CEA level, an estimated 167 would appropriately avoid unnecessary surgery based on FDG PET information (Fig. 2) .
RESULTS
In the FDG PET penalized analysis, the 15% reduction in FDG PET parameters resulted in sensitivity and specificity values of 0.825 and 0.643 in the whole body and 0.819 and 0.838 in the liver. Although the CT-alone strategy remained unchanged, the mean cost of the CT ϩ FDG PET strategy increased to $9,109 and there was a loss in life-year savings, resulting in an overall LE gain of 8.213 days. ICER was calculated at $33,556 per life-year saved (see Table 2 ).
While maintaining the 15% penalization of FDG PET parameters, the 15% inflation of CT parameters resulted in CT sensitivity and specificity values of 0.871 and 0.641 in the whole body and 0.912 and 1 in the liver. The increased diagnostic values of CT versus FDG PET resulted in an ICER of $111,000 per life-year saved. Although the differ- ence in mean cost between the two strategies was similar to the results of the FDG PET penalized analysis, there was a substantial reduction in the difference in LE measures for the two competing strategies.
The remaining results describe the analysis of the most influential tree variables found through sensitivity analysis. Figure 3 plots the prevalence of disease (baseline prevalence ϭ 70.2%) versus the ICER values for the CT ϩ FDG PET strategy. At a prevalence of 91% or higher, the CT ϩ FDG PET strategy not only resulted in LE gains but also accrued cost savings. As the percentage of patients with disease dropped to less than 49%, the ICER for the CT ϩ FDG PET strategy increased to more than $50,000 per year. When the prevalence decreased to 8% or less, the CT-alone strategy became favorable in both overall cost and LE gains. Figure 4 illustrates the effect of varying the sensitivity of CT in the whole body on the ICER for the CT ϩ FDG PET strategy. When the sensitivity of CT in the whole body increased to 0.879 or greater from its baseline value of 75.7%, the ICER for the CT ϩ FDG PET strategy no longer remained less than $50,000 per year. The same effect could be seen for the specificity of biopsy. When this specificity value decreased to 0.803 or lower, the ICER for the CT ϩ FDG PET strategy increased to more than $50,000 per year. Figure 5 plots the cost of FDG PET verses the ICER values of the CT ϩ FDG PET strategy. At the baseline value of $2,000 per FDG PET scan, there were no cost savings, but if the cost was reduced to $1,171, the CT ϩ FDG PET strategy began to produce both cost savings and LE gains. Figure 6 describes the change in ICER values for the CT ϩ FDG PET strategy as a function of the frequency of hepatic recurrence (hepatic involvement). When the frequency of hepatic recurrence exceeded 46%, the CT ϩ FDG PET strategy also produced both cost savings and LE gains.
Finally, two LE variables were found to have an effect on the ICER. When the LE of an untreated patient with recurrence increased to 2.569 years or more from its baseline value of 2.000 years, the ICER for the CT ϩ FDG PET strategy increased to more than $50,000 per year. Likewise, as the LE of a patient with recurrence undergoing chemotherapy decreased from its baseline value of 2.663 years to 1.75 years or less, the CT ϩ FDG PET strategy was no longer cost-effective based on the $50,000 per life-year saved criterion.
A sensitivity analysis was performed on all variables used in our decision tree. Other than the ones described above, no variable affected the ICER enough to prevent the CT ϩ FDG PET strategy from being interpreted as cost-effective. 
DISCUSSION
In the clinical setting, each patient has his or her personal concerns when management decisions are being made. Our analysis did not deal with the social and emotional issues that play a part in the patient's decision-making process. Our intent was to address policy guideline issues for the cost-effective management of recurrent CRC using a population-based approach. This study is not meant to dictate how physicians should manage all patients with recurrent CRC. Rather, it is intended to provide information for the broader view of how this group of patients could more accurately be assessed for surgical selection. Although our population-based model neglects personal preferences and concerns, these factors are crucial to the proper management of individual patients. Our study relies completely on statistical simulation of a selected population; individual variation should and will inevitably occur. This analysis can be used as a guide to the design of clinical trials but is in no way a substitute for them.
The decision trees we used are extremely complex. To qualify the results of our decision tree model, we compared our results with those from published clinical studies. An article by Steele et al 19 looking at the resectability of CRC hepatic recurrence found that approximately 42% (63/150) of patients thought to have resectable disease by CT were found to have unresectable disease at surgery (Table 3 ). In our baseline analysis, approximately 43% (172/401) of patients with hepatic recurrence were incorrectly directed to surgery through the CT-alone strategy (see Fig. 2 ). This is one indirect indication that our baseline strategy (CT alone) was modeled appropriately in relation to what is actually practiced clinically.
We further compared the results of this analysis with three articles dealing with the effect of FDG PET on the management of patients with potentially recurrent CRC. 2, 33, 40 Through direct extraction of relevant data, management change percentages were found for the number of patients with hepatic involvement who were correctly directed away from surgery because of true-positive extrahepatic FDG PET findings (see Table 3 ). These values were similar to the 42% (167/401) that FDG PET found in our decision analysis shown in Figure 2 .
We also determined the percentage of patients who were true surgical candidates but were mismanaged by falsepositive extrahepatic FDG PET findings. Through calculations at the appropriate branch of our decision tree, the percentage of false-positive extrahepatic FDG PET findings was determined. The false-positive rate was 9.2%, compared with 11% of patients mismanaged in the clinical FDG PET studies. These similarities also provide reassurance that the modeling aspect of our decision trees represents what is occurring in real medical practice.
Another way we confirmed proper functionality of our decision trees was by performing sensitivity analysis on certain variables with predictable outcomes. One such variable was the prevalence of disease in our study population. As this value increased, the CT ϩ FDG PET strategy should have become favorable because the use of the additional diagnostic tool would be more beneficial in a population with higher disease rates. As shown in Figure 3 , the CT ϩ FDG PET strategy reached an ICER of greater than $50,000 per year at a prevalence of less than 49%. At a prevalence of more than 91%, the CT ϩ FDG PET strategy accrued both cost savings and an increase in LE gains, whereas this became true for the CT-alone strategy only at an extremely low prevalence of 8% or less. It is well known that FDG PET should not be used as a screening tool.
Two other variables that had a predictable effect on the ICER while performing the sensitivity analysis were the LE values for a patient with recurrence receiving no treatment and a patient with recurrence undergoing chemotherapy. When the LE of a patient with recurrence receiving no treatment reached similar values to the LE of a patient with recurrence undergoing chemotherapy, the ICER for the CT ϩ FDG PET strategy increased to more than $50,000 per year. There was no longer an LE benefit from FDG PET correctly sending patients with recurrence who were missed by CT to chemotherapy. As would be expected, management algorithms become unnecessary when the possible outcomes are the same.
In the current health care environment, FDG PET is not readily available and patients do not always have access to it without a prior hospital stay. This study shows that if FDG PET were more accessible, there would be a potential for significant LE gains, and if the cost of PET could be lowered, cost savings may also accrue. Based on our results, a more widespread dissemination of the technology is warranted. Despite the high cost of FDG PET relative to other imaging modalities, it can be more cost-effective because of the increased performance of detecting and evaluating tumors throughout the body at minimal risk to the patient.
To understand why the CT ϩ FDG PET strategy was not cost-effective through the 15% FDG PET penalized/15% CT inflation analysis, we looked to the sensitivity analysis on the sensitivity and specificity of CT in the whole body. For our analysis, the CT ϩ FDG PET strategy remained cost-effective at values less than 0.879 for the sensitivity of CT in the whole body. As the performance of CT reached these higher end values, the use of the additional FDG PET scan was no longer cost-effective. This is because similar LE gains could be accomplished through the use of the less-costly CT scan alone. However, because of the wide variability in the quality of CT scanners and the interpretation of the findings, it is unlikely that an overall sensitivity value this high for CT in the whole body can be achieved.
With the substantial number of unnecessary surgeries avoided through the use of FDG PET, it seems as if cost savings should result from use of the CT ϩ FDG PET strategy. Our analysis showed the high cost of FDG PET as a primary inhibiting factor. At a Medicare reimbursement rate of $2,000 per FDG PET scan, the initial cost of including an FDG PET scan for all patients thought to have recurrence would be substantial. As seen in Figure 5 , through the sensitivity analysis of the cost of FDG PET, cost savings began to occur when the cost of FDG PET was reduced to $1,171. In addition to the high cost of FDG PET, the population-based model we performed might have led to an overestimation of mean cost for the CT ϩ FDG PET strategy. On an individual patient level, allocating FDG PET scans only to patients who need further evaluation, as determined by the specific situation, might decrease the number of initial FDG PET scans. In reality, the population as a whole will most likely receive fewer FDG PET scans. The overall estimated cost values may in fact turn out to be lower than we have estimated because all patients in our model with a negative CT scan received an FDG PET scan. Although the additional diagnostic value of FDG PET is apparent, these cost issues are, in part, inhibiting the widespread dissemination of FDG PET into the clinical setting.
A possible critique of our study might be that we focused on hepatic recurrences and resectability. Studies show that the liver is the most common site for recurrence of CRC and resection is a beneficial intervention. However, we did not address slightly less common sites of recurrence, such as the lung and pelvic regions. This was mainly due to the lack of data for these regions and the difficulty in creating a decision model that would encompass every possible CRC recurrence site. The meta-analysis by Huebner et al 41 on FDG PET in recurrent CRC shows that many of the FDG PET-directed changes in management decisions occur in patients with disease outside the liver. If it were possible to develop a more generalized model by incorporating these other scenarios, it is likely that we would see additional cost-effectiveness benefits of using FDG PET.
We made several assumptions with regard to biopsy issues that need explanation. We designated them as 100% accurate, and we assumed that a biopsy sample could be obtained for all positive imaging findings. In the clinical setting, biopsy is often but not always used for validation purposes. Because in both strategies biopsy was performed after the imaging studies, we believed that any advantage of using these high sensitivity and specificity values would occur equally in both strategies. However, through the sensitivity analysis of biopsy, we found that decreasing the specificity of biopsy had a greater negative effect on the CT ϩ FDG PET strategy. After a potentially incorrect CT imaging finding, FDG PET correctly redirected some patients to more appropriate management decisions. In our model, when the specificity of biopsy was lower than the specificity of FDG PET, many of the patients who would have benefited from the FDG PET diagnosis underwent an incorrect management change based on the post-PET bi- opsy. In the CT ϩ FDG PET strategy, there are many positive imaging findings to study by biopsy. Further, because FDG PET has a greater sensitivity and specificity in the whole body compared with CT, the biopsy sensitivity and specificity values must be decreased much more before a similar effect would be seen in the CT-alone strategy. Even with the apparent disadvantage of using a biopsy with lower sensitivity and specificity values, the sensitivity analysis showed that biopsy specificity would have to be as low as 0.803 for the ICER to increase to more than $50,000 per year. By choosing a biopsy sensitivity and specificity of 100% in our model, we eliminated the possibility of biopsy having a negative effect on the management decisions made by CT or FDG PET in both strategies. Some other limitations imposed by the assumptions of this decision analysis and tree structure deserve mention. We did not address the issue of "rerecurrence" after surgery of recurrent CRC. Patients who underwent successful surgery were given an LE value based on the 5-year diseasefree survival rate found in Ballantyne and Quin. 42 If more evidence is found to suggest that there are a substantial number of patients who develop rerecurrence, further monitoring of patients after resection of their first recurrence might be warranted. The problem from the decision analysis perspective is the lack of information suggesting how these patients should be monitored. Developing arbitrary management branches may influence the results inappropriately. Because of this and the fact that the same percentage of patients in both strategies underwent successful surgeries, we believed that trying to model rerecurrence would not further clarify or better validate the main results of this study.
Another possible limitation might have arisen from the assumption that patients who were missed would only recycle through the tree once. At first glance it might seem unethical to stop monitoring a high-risk patient after two sets of negative diagnostic tests. However, the probability of having a false-negative result even by the less accurate strategy (CT alone) is negligible at the terminal nodes of the second set of tests. The approximate amount of time a patient would spend while progressing through either of the two competing strategies was estimated at less than 2 years. Time was factored into the analysis only through discounting of LE and cost values. However, patients entering our decision tree were monitored with basic clinical testing such as CEA levels for as long as 5 years after their primary CRC surgery. It is thought that more than 90% of recurrences will have developed within this time. 4, 43 Therefore, patients who are truly found not to have disease will most likely not develop recurrent CRC following the management strategies described by our decision trees.
Finally, the variable for the percentage of resectable liver-only disease resulted in predictable outcomes. Two important points should be addressed here. As the percentage of resectable liver-only disease decreases to low values, the CT ϩ FDG PET strategy should become less cost-effective. If hepatic resection is not a benefit to the patients in the population, there would be less LE gain by using a more extensive management strategy for identifying patients for curative surgery. This was demonstrated through a sensitivity analysis of the percentage of resectable liveronly disease. However, as noted in the introduction, many articles in the literature show the benefits of hepatic resection for these patients.
The second point can be used as a further validation for the results of our study. Although decreasing the percentage of resectable liver-only disease increases the ICER, it does not result in a value greater than the cutoff value of $50,000 per year. The reasoning is that the benefits of using FDG PET come from better identification of patients with recurrence limited to the liver, regardless of whether the liver recurrence is resectable or not. Patients misclassified as being surgical candidates by CT based on the diagnosis of liver-only recurrence, who are found by FDG PET to have recurrence outside the liver, avoid further unnecessary liver evaluations and surgeries. When more information is available about the ability of competing imaging modalities to determine liver-only resectability, a future study can be conducted including this aspect of management in our current decision tree models.
In conclusion, our results have shown quantitatively, through decision tree modeling, the relative cost-effectiveness of using a CT ϩ FDG PET strategy for managing patients thought to have recurrence who are potential candidates for surgical hepatic resection. Many might argue that comparing a single imaging strategy with a strategy that uses two imaging techniques is unfair. What needs to be emphasized is that the metabolic information provided by FDG PET can be independent of the anatomic information acquired through the CT technique. Using the CT ϩ FDG PET strategy can potentially save many of these patients from undergoing unnecessary surgeries. Although currently the initial cost of FDG PET is substantial, a decrease in the cost of FDG PET or in the number of FDG PET scans per study population might lead to cost savings. By avoiding medical expenses from these unnecessary surgeries through the increased ability to detect recurrent disease throughout the entire body, these initial FDG PET costs might be overshadowed, potentially leading to national medical cost savings of millions of dollars per year. A greater LE value for these patients as a whole might also result from the better diagnosing and staging. Our results were shown to be robust over a wide range of parameter values. The decision trees created may serve as a guide for developing clinical trials as well as determining the cost-effectiveness of new emerging technologies.
